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ABSTRACT 
 As malaria, caused by Plasmodium spp., continues to afflict millions of people worldwide, 
there is a dire need for the discovery of novel, inexpensive antimalarial drugs.  Although there 
are effective drugs on the market, the consistent development of drug resistant species has 
decreased their efficacy, further emphasizing that novel therapeutic measures are urgently 
needed.  Natural products provide the most diverse reservoir for the discovery of unique 
chemical scaffolds with the potential to effectively combat malarial infections, but, due to their 
complex structures, they often pose extreme challenges to medicinal chemists during 
pharmacokinetic optimization. In our laboratory we have performed unbiased, cell-based assays 
of numerous synthetic compounds from chemical libraries enriched with nature-like elements.  
This screening has led to the discovery of many original chemical scaffolds with promising 
antimalarial properties.  In an attempt to further characterize these scaffolds, the most promising 
compounds were assayed in order to determine their cytotoxic effects on mammalian cells. In 
addition, the development of a drug resistant parasite line of Plasmodium falciparum to the most 
promising compound was done in order to determine the relative probability for parasite 
resistance development. 
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CHAPTER ONE: INTRODUCTION 
 According to the most recent statistics presented by the World Health Organization 
(WHO) in their annual World Malaria Report 2011, an estimated 3.3 billion people, or roughly 
half of the global population, are living in areas which are considered at risk of malaria 
transmission, and, of the 216 million confirmed reports of malaria infection, approximately 
655,000 proved to be fatal (WHO 2011).  Additionally, 86% of the 655,000 deaths that were 
reported in 2010 occurred in children under 5 years of age (WHO 2011).  The majority (~95%) 
of these infections and subsequent fatalities occurred in the poverty-stricken countries of Africa 
and Southeast Asia due to inadequacies in disease prevention, surveillance and treatment within 
the given countries’ healthcare systems (Snow, Guerra et al. 2005).  These grim statistics become 
even more troublesome when one considers that the data for these estimates comes strictly from 
those cases which were formally documented and reported through national malaria control 
programs, and, thus, the actual prevalence of clinical episodes and fatalities may be up to 50% 
higher than the original estimates (Snow, Guerra et al. 2005).  The most effective remedy for 
such dire statistics is the discovery of novel, inexpensive and effective antimalarial 
chemotherapies.  
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An Overview of the Malaria Parasite: Plasmodium spp. 
 Plasmodium spp. is the causative agent of one of the most infamous infectious diseases to 
have ever plagued mankind, malaria.  It is classified as a unicellular eukaryotic apicomplexan, 
and, although there are many different species of Plasmodium which afflict humans, including P. 
vivax, P. ovale, P. malariae and P. knowlesi, the most burdensome has proven to be P. 
falciparum.  P. falciparum is by far the most virulent of all the species known to afflict humans, 
and it alone is responsible for approximately 85% of global malaria fatalities, roughly 600,000 
per year (Rich, Leendertz et al. 2009). 
The Plasmodium Life Cycle 
 Before discovering a truly novel and effective antimalarial, the parasite’s extremely 
complex life cycle must first be examined and understood. The life cycle involves multiple 
stages which occur in multiple hosts, but it ultimately begins with the infection of its primary 
vector, female mosquitos of the genus Anopheles.  Once the female mosquito obtains a blood 
meal from an infected host, Plasmodium sexual stages (gametocytes) that are comprised of the 
highly motile microgametocyte (male) and the nonmotile macrogametocyte (female) are 
ingested, and they subsequently fuse to form a mature ookinete which is the parasite’s diploid 
zygote (Matuschewski 2006).  The mature ookinetes then go on to invade the basal lamina of the 
mosquito’s midgut cells where they implant and begin to continue to develop into oocysts.  
These oocysts undergo multiple mitotic divisions to form sporoblasts and, ultimately, sporozoites 
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(Matuschewski 2006).  Sporozoites free themselves from the oocyst and invade the mosquito’s 
salivary gland where they reside and await inoculation into a human host.   This particular part of 
the life cycle is collectively referred to as the sporogonic cycle.   
 The life cycle continues once the infected female Anopheles mosquito takes a blood meal 
from a human host.  Upon obtaining the blood meal, the sporozoites within the mosquito’s 
salivary glands are inoculated into the underlying blood capillaries.  Eventually, the sporozoites 
are carried within the circulation to the liver sinusoids.  The liver sinusoids contain cells known 
as Kupffer cells which are resident macrophages, and these cells interact with the sporozoites to 
effectively serve as a bridge between the sinusoid lumen and the liver hepatocytes (Frevert 
2004).  The sporozoite within the hepatocyte then begins to undergo a form of schizogony via 
multiple DNA replications to produce a cluster of thousands of merozoites collectively called a 
merosome (or schizont) (Meis and Verhave 1988).  These merosomes have been shown to 
protect the inner merozoites from phagocytosis, and eventually they are expelled from the host 
hepatocyte back into the lumens of the liver sinusoids (Sturm, Amino et al. 2006).  After a short 
time, the merosome ruptures and the merozoites are released into the bloodstream to infect the 
host’s erythrocytes.  This portion of the cell cycle is collectively called the exoerythrocytic 
stages, or more simply liver stages, of the parasite.   
 The newly freed merozoites within the bloodstream mark the beginning of the next phase 
of the cell cycle known as the erythrocytic phase.  First, the merozoite enters the host erythrocyte 
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and begins its transition to the first stage of this portion of the cell cycle which is known as ring 
stage for its resemblance to a ring when stained and viewed microscopically.  Growth continues 
on from the ring stage to the second stage known as the trophozoite.  During this stage, the 
trophozoite actively takes up the erythrocyte cytoplasm and utilizes the hemoglobin it obtains as 
a source of amino acids (Perlmann and Troye-Blomberg 2002).  Additionally, the trophozoite 
stage is where DNA replication begins in order to produce more merozoites.  The trophozoite 
stage begins to transition to the final schizont stage when schizogony is initiated.  Similar to the 
schizont formed during the exo-erythrocytic stages within the hepatocyte, the multinucleated 
erythrocytic schizont is an aggregate of numerous merozoites.  It is formed via multiple rounds 
of DNA replication with no accompanying cytokinesis, and is a stage in the parasite’s life cycle 
which is unique among all other eukaryotes.  Eventually, the schizont, along with the 
erythrocyte, ruptures and releases the merozoites into the bloodstream to  infect even more 
erythrocytes.  This stage of the infection is ultimately when most symptoms become empirically 
noticeable, and it is the primary stage of the parasites life cycle that is targeted by past and 
present antimalarial chemotherapies. 
Present State of Malaria Control and Prevention Efforts 
 The first moderately effective effort to globally eradicate malaria came in the 1950s when 
the World Health Organization (WHO) introduced a program called the Global Malaria 
Eradication Program (WHO 1999).  Through this effort, chloroquine was used extensively in 
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order to treat infections due to its unprecedented efficacy at the time. In addition, the now banned 
insecticide known as DDT (dichlorodiphenyltrichloroethane) was used in order to control the 
Anopheles population (WHO 1999).  However, the program ultimately ended in the 1970s due to 
the emergence of drug resistant parasites and Anopheles vectors.  More recently, in 1999 an 
effort known as the Medicines for Malaria Venture (MMV) was created.  As its name implies, 
this movement aims to discover and develop novel inexpensive antimalarial therapeutics in order 
to help the impoverished and most afflicted nations of Africa and Southeast Asia.  To date, the 
MMV has been responsible for the development and delivery of antimalarials to many of these 
countries.  However, the organization’s insufficient funding seems to limit their ability to help on 
a worldwide scale. 
 Other efforts at malaria prevention include the recently developed RTS,S/AS01 vaccine 
by GlaxoSmithKline (GSK).  This particular attempt at an effective vaccine mimics the 
parasite’s circumsporozoite protein that bears the highest concentration of all surface antigens on 
the sporozoite (Stout, Slaoui et al. 1997).  Although the vaccine has yet to be clinically approved, 
it recently completed the first stages of Phase III clinical trials in January 2011.  Through these 
trials, two age groups (6-12 weeks and 5-17 months) were given the three doses that comprise 
the complete vaccination over a three-month time period (one dose each month).  However, only 
the results for the older age group have been presented because only this age group has 
completed the required 12-month follow-up (Agnandji, Lell et al. 2011).  Nonetheless, the 
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reported vaccine efficacy against clinical malaria cases in this age group was 55.1%, and the 
efficacy against severe malaria cases was reported to be 34.8% (Agnandji, Lell et al. 2011).  
Despite the fact the results are not complete due to a lack of results from the younger age group, 
it is clear that the vaccination is not as effective as one would hope.  While the vaccine 
undoubtedly has the ability to save many lives and much suffering, considering the time it will 
take to get out of clinical trials and the modest results demonstrated thus far, other developments 
to prevent and treat malaria are still dramatically needed. 
 Vector control is yet another means of preventing the spread and prevalence of malaria 
infection.  The most common form of vector control is the use of insecticide-treated bed nets; the 
majority of which are currently being distributed at no charge in 82 countries throughout the 
world (WHO 2011).  However, some of these bed nets have issues with longevity of use, and 
others have seen the development of vector resistance to certain insecticides (WHO 2011).  In 
addition to insecticide-treated bed nets, indoor residual spraying of certain insecticides (including 
the infamous DDT) has also been employed in order to control the Anopheles population.  
However, unlike the insecticide bed nets, indoor residual spraying is much less prevalent 
throughout the most afflicted nations in the world due to the expense of the insecticides and the 
lack of capital by the consumer. 
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 With all other control efforts seeing such limited success, it becomes more obvious than 
ever that there is a dire need for the discovery and development of novel antimalarial 
chemotherapies. 
Current Antimalarial Chemotherapies: Efficacy and Resistance Development 
 To date, the most effective prevention and treatment method for malaria infection has 
proven to be the discovery and development of novel compounds which display potent 
antimalarial activity.  In fact, there have been multiple antimalarial compound discoveries within 
various chemical families since the onset of antimalarial drug discovery research.  The most 
common and widely used antimalarial chemical families include the quinolines, antifolates and 
artemisinins. 
 The quinoline family of antimalarial compounds possesses some of the most effective 
compounds to date, including quinine, chloroquine, mefloquine and primaquine.  Quinine should 
be noted before all others when discussing the quinoline family because it is the parent 
compound from which all the others were eventually derived (Ridley 2002).  Quinine was 
originally extracted from the bark of the Cinchona tree in the 1930s, but, due to its rather long 
regimen time, which requires three administrations per day for a week or more, the search for 
more potent structural analogs began (Meshnick 1998; Ridley 2002).  Perhaps the most overall 
effective drug to be developed thus far is chloroquine (CQ), a 4-aminoquinoline, which 
dominated antimalarial treatments beginning in the late 1930s (Hartl 2004).  Ultimately, CQ 
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works by interfering with the biocrystallization process of heme within the parasite’s digestive 
vacuole that leads to a toxic buildup of heme, ultimately sealing the fate of the parasite (Wellems 
and Plowe 2001).  In fact, this mechanism of inhibition has also been shown to be possessed by 
other quinolines such as quinine, mefloquine and primaquine (Dom, Vippagunta et al. 1998). CQ 
was used almost exclusively for 20 years because of its unmatched efficacy; however due to 
resistance development emerging first in the 1950s in both South America and Southeast Asia, 
followed by Africa in the 1970s, alternatives to CQ became a necessity (Wellems 2002).  CQ 
resistance specifically is generated via multiple point mutations in the parasite’s PfCRT (P. 
falciparum CQ resistance transporter) gene whereby the parasite acquires the ability to pump out 
CQ to restore the parasite’s heme detoxification process (Fidock, Nomura et al. 2000).  Another 
commonly used quinoline is mefloquine (MQ).  MQ was proven effective in parasites which are 
CQ resistant, but studies have shown that additional resistance to it develops extremely fast 
(Wellems 2001; Price, Uhlemann et al. 2004).  Additionally, primaquine has been proven 
effective, but, if it is not used in conjunction with other antimalarials such as CQ or MQ, it is 
minimally effective due primarily to an extremely large relapse rate (Baird and Hoffman 2004).  
Although the quinoline family of antimalarials has historically demonstrated great success in the 
past, resistance development has been reported to each and every one, so the need for even more 
effective drugs lingers on. 
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 A second class of antimalarial compounds is collectively known as the antifolates.  
Antifolates are usually administered in fixed ratio combinations of their two distinct classes: the 
dihydropteroate synthase (DHPS) inhibitors and the dihydrofolate reductase (DHFR) inhibitors 
(also called class I and class II antifolates, respectively) (Winstanley and Ward 2006; Nzila 
2006).  Antifolates are used in combination of the two subclasses because together they have a 
synergistic effect by inhibiting two separate parts of the folate pathway; this fact also helps slow 
the emergence of resistance (Ridley 2002). In accordance with their name, these drugs act by 
inhibiting their respective enzymes, and this inhibition ultimately leads to the interference of 
DNA synthesis via the depletion of essential cofactors (Winstanley and Ward 2006).  Though 
there are many combinations of antifolates used, the most common is pyrimethamine-
sulphadoxine; pyrimethamine represents the DHFR-inhibitor portion while sulphadoxine acts as 
the DHPS-inhibitor.  Originally, this combination showed a greater efficacy than that of CQ, but 
resistance has been routinely reported since their introduction in the most afflicted countries 
(such as those in Africa and Southeast Asia) where resistance is much more prevalent (Wellems 
2001).  Similar to the antimalarials which came before them, resistance to both has been reported 
to occur due to multiple mutations within specific genes (the dhfr gene for pyrimethamine and 
the dhps domain of the dhps-pppk gene for sulphadoxine) (Nzila 2006).   
 The present day gold standard for Plasmodium infection lies within the family of 
compounds known as the artemisinins.  The artemisinin family is based on the compound 
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artemisinin itself, which is derived from a naturally-occurring variety of wormwood known as 
Artemisia annua (or qinghao) (Price 2000).  Its original discovery and potency demonstration 
against malaria in the 1970s immediately led to the development of its near equally potent 
semisynthetic derivatives, including artesunate and artemether (Dondorp, Yeung et al. 2010).  
Although the exact mechanism of antimalarial action of the artemisinins is still being debated, it 
has undoubtedly been shown to affect both the erythrocytic stages and the gametocytes of the 
parasite in such a way which has never been seen before (Olliaro 2001).  However much like 
every antimalarial which came before them, the artemisinins have their disadvantages.  The 
primary drawback to using artemisinin or one of its derivatives exclusively is their extremely 
short half-life in comparison to previous antimalarials; regardless of whether one of the 
semisynthetic derivatives is used or artemisinin itself, all are rapidly metabolized to the primary 
effective agent known as dihydroartemisinin (DHA).  However, DHA also has an extremely 
short half-life of about one hour (Ridley 2002; Dondorp 2010).  This problem ultimately leads to 
an undesirable extended treatment plan that historically has shown poor patient compliance 
(RBM/WHO 2001).  To remedy this problem, drugs from this family of compounds are given in 
combination with other known antimalarials that have a much longer half-life (Price and Douglas 
2009).  This combonatorial treatment plan has been deemed artemisinin combination therapy (or 
ACT), and it is currently the first line of defense against most Plasmodium infections.  The most 
common derivative used is artesunate, and it is frequently paired with either CQ, amodiaquine 
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(another 4-aminoquinoline related to CQ), MQ or SP (RBM/WHO 2001).  Despite the ACTs 
unprecedented initial success, decreased sensitivity (parasite resistance) to ART and its 
derivatives was discovered in Cambodia starting in 2004 (Dondorp, Nosten et al. 2009).  The 
exact mechanism of resistance is currently still being studied, but current evidence suggests 
multiple mutations in multiple genes such as PfMDR1, PfCRT and PfSERCA (sarcoendoplasmic 
reticulum calcium ATPase-6) (Dondorp, Nosten et al. 2009).  However, this resistance has been 
reported to be incomplete because worldwide treatment success rates remain, on average, above 
90% (Dondorp, Yeung et al. 2010).  Nevertheless, resistance is indeed emerging to this class of 
drugs just like all others previously, so the need for the discovery and development of even more 
drugs is still a primary goal. 
Nature-inspired Antimalarial Therapeutics 
 Nature has played a key role in antimalarial drug discovery since the very beginning.  One 
of the first antimalarials ever discovered, quinine, was extracted from the bark of the Cinchona 
tree.  Additionally, the most potent antimalarial to date, artemisinin, was also extracted from a 
natural source.  However, these compounds were just the leads that set the stage for the evolution 
of entire classes of antimalarials.  After each was discovered, they were subsequently modified 
using medicinal chemistry techniques to develop multiple semisynthetic compounds that 
displayed even higher parasite potencies (Kaur, Jain et al. 2009).  However, quinine and 
artemisinin are only the most notable examples; many other lead compounds that display 
extremely potent antimalarial properties have been discovered from many other natural sources, 
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such as other terrestrial and marine extracts (Kaur, Jain et al. 2009).  History has proven that 
nature possesses the remedy for problems of its own creation; the only obstacles in the way of 
development of those remedies are lack of interest in research and development by the 
pharmaceutical industry as well as undesirable preliminary chemical properties. 
 One of the pharmaceutical industries’ key qualms against the screening of natural products 
for antimalarial activity is that a discovery could be highly reproducible, thereby preventing 
patent attainment (Li and Vederas 2009).  However, as past antimalarial families have shown, 
the initial discovery is just the beginning.  Often times the crude extract, such as quinine for the 
quinolines and ART for the artemisinins, only represents a parent compound or scaffold from 
which other semisynthetic derivatives with even greater efficacies can be generated.  These 
derivatives can then, in turn, be patented and marketed at the pharmaceutical companies leisure.  
Nevertheless, their lack of interest lingers on, and, until this changes, it will remain exponentially 
harder to efficiently develop new antimalarials of the nature-inspired genre. 
 Additionally, many compounds that are isolated from natural sources display undesirable 
qualities including cytotoxicity, inadequate bioavailability and poor chemical properties (Kaur, 
Jain et al. 2009).  This comes as no surprise due to the fact that nature has consistently shown to 
have much more complex and diverse molecules than any which can be achieved via synthetic 
approaches alone (Thomas and Johannes 2011).  However, all of these drawbacks have a simple 
remedy made possible by synthetic strategies of modern day medicinal chemistry.  During a 
process known as lead optimization, medicinal chemists are able to modify the original 
extract/alkaloid’s primary chemical scaffold with various functional groups and/or chemical 
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(potentially nature-like) moieties.  If successful, these modifications can potentially serve to 
improve the given compounds pharmacokinetic properties as well as antimalarial potency. 
 The seemingly endless amount of novelty displayed by nature should never be 
underestimated, and plants and animals alike should continue to be looked at for inspiration for 
nature-inspired synthetic libraries.  Regardless of whether they may hold the cure for malaria or 
some other deadly disease, it is certain that so long as there is limited research and industrial 
disinterest within the field there will also be limited success. 
Summary and Significance of Project 
 Despite the various efforts for malaria eradication, none have proven to be as effective as 
originally thought, and the discovery, characterization and development of novel inexpensive 
antimalarial therapeutics remains the world’s best hope in one day eradicating the malaria 
parasite.  Although numerous effective drugs have been developed thus far, resistance emergence 
has been documented to every single one, and this fact simply underscores the dire need for new 
compounds.  The non-canonical life cycle of Plasmodium provides drug discovery researchers 
with a seemingly endless supply of potential targets.  Likewise, the unprecedented chemical 
novelty provided by natural alkaloids and their semisynthetic nature-inspired derivatives 
provides the largest reservoir of compounds to potentially exploit and inhibit a specific part of 
the parasite’s extensive life cycle.  In accordance with these facts, this particular study aims to 
characterize potential lead compounds for their further development into next generation 
antimalarials. 
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CHAPTER TWO: MATERIALS AND METHODS 
Asinex Nature-Inspired Chemical Libraries 
 In 2011, our drug discovery lab was given the unique oppurtunity to probe ASINEX’s 
extremely diverse chemical libraries for compounds displaying high probability of antimalarial 
activity.  The compound libraries, totaling over 70,000, were filtered based upon the following 
specifications: high oxygen content (preferably greater or equal to three oxygens), enriched with 
natural product-like chemical moieties, and absence of peroxide bridge(s).  These specifications 
were selected for based upon the chemical qualities that have been displayed in other potent 
antimalarial compounds.  This screen yielded 592 total compounds.  However, the relatively 
recent screening of the Tres Cantos antimalarial compound set by GlaxoSmithKline led to the 
added specification of compounds which have high hydrophobicity indices (ClogP equal to or 
greater than 3.5) (Gamo, Sanz et al. 2010).    Upon application of the additional hydrophobicity 
index preference, only 191 of the 592 compounds displayed the desired characteristics.  These 
were ordered and screened against P. falciparum 3D7 (drug-sensitive) and Dd2 (multidrug 
resistant) strains.  This preliminary screen identified six novel scaffolds with parasite potency 
within nanomolar range.  More than six compounds displayed nanomolar potency, but similar 
scaffolds led to the selection of those that were the most potent.  Considering the results from 
this preliminary parasite screening, the remaining 401 compounds were ordered and screened in 
the same manner.  Upon their initial screening, three more novel scaffolds were discovered for a 
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grand total of nine unique structures.  These nine compounds were designated as the parent 
compounds.  
Culturing and Subculturing of NIH 3T3 Embryonic Mouse Fibroblasts 
 In order to determine the cytotoxic properties of these potential antimalarial compounds 
on mammalian cells, an embryonic mouse (Mus musculus) fibroblast cell line, more specifically 
NIH 3T3, was employed.  This specific cell line was chosen for the cytotoxicity assays primarily 
because Mus musculus is the most commonly used animal research model, so preliminary 
cytotoxicity assay data with this cell line is expected to most adequately reflect cytotoxicity 
values which will be obtained in future mammal studies for these same compounds.     
 Culture guidelines set forth by the American Type Culture Collection (ATCC) were 
strictly followed.  The cells were cultured using Dulbecco’s Modified Eagle’s Medium (DMEM) 
which was further modified to possess 4500 mg/L glucose, 4 mM L-glutamine, 1 mM sodium 
pyruvate, 1500 mg/L sodium bicarbonate and 10% v/v heat-inactivated newborn calf (bovine) 
serum.  Furthermore, the cells were incubated and maintained in a humidified 5% carbon dioxide 
(CO2) environment at 37ºC.   
 The cells were never allowed to achieve 100% confluency; in fact, the cells were strictly 
maintained below approximately 80% confluency.  Once the culture achieved a near 80% 
confluency, the cells were then subcultured.  Subculturing of NIH 3T3 fibroblasts involves 
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multiple steps.  First, the old/used medium was removed using a Pasteur pipette.  Next, the cells 
were washed with approximately 4 mL phosphate buffered saline (PBS) in order to remove any 
excess medium that contains proteins that act as a trypsin inhibitor in the next step if not 
removed.  Once the cells have been adequately washed with PBS, they were treated with 1X 
trypsin-EDTA (~4 mL) for 30 seconds.  After the initial 30 seconds, most of the trypsin was 
removed using a Pasteur pipette and the plate containing the cells was placed into a 37ºC 
incubator for 2 minutes to facilitate increased trypsin activity.  The plate containing the cells was 
then removed from the incubator, and the cells were removed from the plate by resuspending 
them in approximately 7 mL of the modified DMEM described previously.  A small portion of 
this culture resuspension, typically 1 mL, was retained in order to maintain the culture. 
Promega CellTiter AQeous Non-Radioactive Cell Proliferation Assay 
 This primary cell proliferation/viability assay, also commonly called the MTS assay, 
utilizes a specific tetrazolium salt known as MTS (3-(4,5-dimethylthiazol-2-yl)-5-(3-
carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium) along with an electron-coupling 
reagent known as phenazine methosulfate (PMS) in order to measure dehydrogenase activity 
which is only observed in metabolically active (viable) cells.  In viable/living cells, 
dehydrogenase activity causes the reduction of MTS into a purple formazan crystal product that 
is soluble in cell tissue culture media.  Subsequently, the presence of this formazan crystal 
product can be assayed by measuring absorbance at 492 nm.  Considering that the amount of 
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formazan present is directly proportional to the quantity of viable cells, the absorbance values 
measured and dose-response curve generated can be used to extrapolate the half maximal 
inhibitory concentration or cytotoxic effect of specific compounds on the given mammalian cell 
line. 
 For this particular cell viability assay, NIH 3T3 embryonic mouse fibroblast cells were 
added to a 384-well tissue treated transparent bottom plate at an approximate cellular 
concentration of 2,500 cells per well for a total volume of 25 μL per well.  These cell seeded 
plates were then placed into a 37ºC, 5% CO2 for 24 hours in order to facilitate attachment of the 
fibroblasts as well as limited proliferation.  After this initial 24 hour period, the plates were 
removed and the compounds which were to be assayed were added to each well in triplicate 
manner.  Three separate concentrations were used for each given compound: 1 μM, 10 μM and 
100 μM in order to generate a dose-response curve from which half maximal inhibitory 
concentration can be extrapolated.  The positive control that was used for this assay was 60 
ng/μL digitonin.  Additionally, DMSO controls of 1% v/v, 0.75% v/v and 0.5% v/v were used to 
negate any toxicity by the compounds’ solvent.  Once the appropriate amount of compound had 
been added to each well, the plate was then placed back into the incubator where it was left for 
48 hours.  After this 48-hour incubation time, the plate was removed from the incubator and 
approximately 10 μL of MTS solution/reagent was added to each well.  The plate was then 
placed back into the incubator for approximately 2 hours to allow the assays reaction to take 
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place.  Immediately following this final incubation period, the plate was again removed from the 
incubator and placed in a BioTek Synergy H1 Hybrid Multi-Mode Microplate Reader in order to 
measure absorbance at 492 nm.  The absorbance results were then extracted into an appropriately 
labeled Microsoft Excel spreadsheet and analyzed using GraphPad’s Prism software. 
Promega Kinase-Glo® Luminescent Kinase Assay 
 In order to confirm the validity of the previously described MTS assay in antimalarial 
cytotoxicity screening, Promega’s Kinase-Glo® assay has been employed.  Fundamentally, this 
assay takes advantage of a reaction that is catalyzed by the enzyme known as luciferase, 
specifically Ultra-Glo™ Recombinant Luciferase.  Although this assay is not specifically 
intended for assaying cytotoxicity, the luciferase enzyme being used can be combined with a 
specific ‘luciferase-safe’ cell culture lysis reagent (CCLR) from the manufacturers separate 
Luciferase Assay System to lyse a cell culture while not interfering with the luciferase reaction.   
When a cell culture is used in combination with Kinase-Glo® luciferase and substrate as well as 
a specific buffer and cell culture lysis reagent (all of which have been deemed proprietary), the 
result is a reaction between the ATP from the cell culture lysate and the Kinase-Glo® solutions 
that results in the production of a measurable luminescent signal.  This reaction occurs only in 
the presence of ATP that is found solely in metabolically active (or viable) cells, and, thus, it can 
be used to assay the selectivity of potential antimalarial compounds.  Additionally, the specific 
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luciferase reaction provided by this system has been proven to be compatible (by the 
manufacturer) with the ASINEX compounds primary solvent, DMSO (dimethylsulfoxide). 
 This modified Kinase-Glo® assay was achieved in combination with the same culture of 
NIH 3T3 embryonic mouse fibroblasts used in the previously described MTS assay.  Initially, the 
fibroblast culture was diluted to an approximate concentration of 50,000 cells/mL; the cellular 
concentration was determined using trypan blue exclusion with a hemacytometer.  This 
suspended culture was then aliquoted into a 384-well solid white tissue culture-treated plate in 
such a way that each well contained a total volume of 50 μL, or approximately 2,500 cells per 
well.  These plates were then incubated in a humidified 37°C, 5% CO2 environment for 24 hours 
to facilitate fibroblast attachment.  Next, the compounds to be assayed were added in triplicates 
of the following concentrations: 100 μM, 75 μM, 50 μM, 25 μM and 10 μM.  Negative controls 
were employed in the form of wells containing only the modified DMEM cell culture medium 
(no cells) and wells containing suspended culture in the absence of any compound or inhibitor.  
The positive control wells contained the known cytotoxic agent digitonin (20 mg/mL).  
Additionally, DMSO controls were used at concentrations of 1% v/v, 0.75% v/v, and 0.5% v/v to 
account for any cytotoxicity conveyed by the compounds primary solvent.  After all compounds 
and controls were properly added, the plates were returned to the incubator for an additional 48 
hours.  After this incubation period, each well’s volume was aspirated so that only the attached 
(viable) fibroblasts remained and the wells were washed with a PBS solution.  Next, the cells 
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were treated with 20μL of the CCLR and shaken for 15 minutes to ensure adequate cell lysis.  
The Kinase-Glo® reagents were than added in 1:1 ratio (20 μL) to the cell lysate for a final well 
volume of 40 μL.  The plates were shaken for an additional 10 minutes which was followed by  
measuring luminescence with a BioTek Synergy H1 Hybrid Multi-Mode Microplate Reader.  
The results were subsequently analyzed with Microsoft Excel and GraphPad Prism software. 
Generation of Drug Resistant Parasite Lineage and Parasite Culturing 
 The generation of a drug resistant parasite line is an approach used for the determination 
of drug-specific parasite resistance potential and drug target identification.  In order to generate 
this resistant parasite, a known multidrug resistant strain of Plasmodium falciparum, Dd2, was 
employed.  The strain was subjected to the most potent antimalarial compound discovered within 
the Asinex nature-inspired chemical libraries via two separate approaches deemed the step-wise 
approach and the intermittent approach.  In order to increase the likelihood of resistance 
development and facilitate the parasite’s mutation rate, the parasite was grown up to a point 
where there was a total number of infected erythrocytes equaled approximately 10
10
 prior to the 
first administration of compound.  The Dd2 parasite strain was originally derived from the W2 
strain, and the W2 strain has been shown to develop drug resistance to other inhibitors when as 
little as 10
6
 infected erythrocytes are initially used (Certain and Sibley 2007; Gassis and Rathod 
1996). 
 For the step-wise approach, the asynchronous parasite population was continuously 
subjected to a concentration of drug that gradually increased as time progressed.  First, the 
population was treated with the predetermined IC25 of the given compound each day for 10 days.  
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After this initial 10 day treatment, the dosage was increased to the predetermined IC90.  This 
dosage was administered each day for approximately 2 weeks or until a parasitemia (percent of 
infected erythrocytes) of 1-2% was achieved.  The concentration was then increased to 5 x IC90 
until a healthy, resistant parasite lineage emerged.  Additionally, the given cultures were treated 
with the specific compound with each medium change. 
 For the intermittent approach, the asynchronous parasite population was treated with 5 x 
IC90 in an intermittent manner.  The initial population was treated with the specified amount for 
seven days in order to ensure at least three generations of parasite were subjected to the 
compound during each round of treatment.  After a week of treatment at this very high 
concentration, the parasitemia was, as expected, reduced to a value which was nearly 
unidentifiable.  The treatment was then stopped to allow the population to return to a parasitemia 
of 2-4%.  Once this occurred, another round of treatment was administered, and the process 
repeated itself until a healthy, resistant parasite lineage emerged.  Additionally, the cultures were 
treated with the specific compound with each medium change during each seven day cycle. 
 The Dd2 culture was maintained in a modified RPMI 1640 medium, collectively known 
as RP0.5A, with the following composition: 1X RPMI 1640, 0.5% w/v Albumax, 300 mg/L L-
glutamine, 25 mM HEPES, 0.2% w/v dextrose, 0.2% w/v sodium bicarbonate, 15 mg/L 
hypoxanthine and 25 g/mL gentamycin.  In addition, the culture was maintained at a 4% 
hematocrit with washed type A+ blood from the local Florida Blood Center.  The medium was 
changed everyday to ensure healthy parasites. 
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Invitrogen SYBR Green I-Based Fluorescence Assay 
 This fluorescence-based assay was used to determine and compare the half maximal 
inhibitory concentrations of the most effective compound discovered in the Asinex libraries on 
the DD2 P. falciparum strain before and after the drug resistance development approaches, and 
on Dd2 and 3D7 to determine relative IC50s of the parent compounds and their respective 
analogs.  It utilizes a special cyanine dye called SYBR Green-I that acts as a DNA intercalating 
agent.  Fundamentally, the assay exploits the fact that erythrocytes lack nucleic acids, whereas 
Plasmodium does not.  Since the culture being assayed contained only Plasmodium parasites and 
erythrocytes, the only DNA present belonged solely to the parasite.  After complex formation 
between the dye and DNA, a fluorescent signal is generated which can be measured at 520 nm 
using a microplate reader.  The fluorescence measurements obtained have been shown to be 
directly proportional to the level of parasitemia over a wide range of parasitemias.  With this data 
graphed upon a dose-response curve, the elucidation of a specific compound’s IC50 is made 
possible.  Validation for this assay has been extensively considered, and past studies have proven 
time and time again that is more than adequate for high throughput screening antimalarial assays 
(Bennet, Paguio et al. 2004; Johnson, Dennull et al. 2007; Co, Dennull et al. 2009). 
 This assay allows the use of only one reagent that contains both the SYBR Green-I dye as 
well as cell lysis components.  Initially, the lysis buffer was prepared to the following 
specifications: 20 mM Tris pH 7.5, 5 mM EDTA, 0.008% w/v saponin and 0.08% v/v Triton X-
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100.  Immediately before the buffer was added to the plates to initiate the assay, 1 L of 10000X 
SYBR Green-I dye was added per 10 mL of lysis buffer for a 1X final concentration of dye.  Due 
to the light sensitive nature of SYBR Green-I, precautions were taken to limit the dye’s exposure 
to direct light. 
 In order to prepare the parasites for this assay, the original culture was first Giemsa stained 
and examined microscopically to determine the approximate level of parasitemia.  In addition, a 
small volume of culture was also loaded into a hemacytometer in order to microscopically 
determine the culture’s hematocrit.  Once accurate values for both parasitemia and hematocrit 
were obtained, calculations were made so that the culture’s parasitemia could be reduced to 1% 
and the hematocrit diluted to 2%.  Immediately after preparing the culture, the drug dilution 
plates were prepared by aliquoting (in triplicates) the required amount of compound into their 
respective wells.  The final concentrations included 0.5 μM, 1.0 μM, 5.0 μM and 10.0 μM for the 
resistant parasite line assay plate and 0.1 μM. 0.25 μM, 0.5 μM, 1.0 μM and 2.5 μM for all 
preliminary assays of the Asinex compounds.  The control used for each SYBR assay was 10 μM 
chloroquine.  The dilution plates were constrained to only four concentrations for the drug 
resistant line due to limitations in compound (UCF201) availability.  The previously modified 
culture was then pipetted into a 96-well black bottom plate so that each well contained a final 
culture volume of 100 μL.  The plate was then allowed to incubate in a humidified 37°C, 5% 
CO2 environment for 72 hours to ensure compound interaction with the parasite’s complete 
erythrocytic life cycle (~48 hours).  Following this incubaiton period, the plates were placed in a 
-80°C freezer overnight.  The following day the plates were thawed and subsequently lysed with 
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the aforementioned SYBR lysis buffer.  To adequately lyse all red blood cells, 100 μL of buffer 
was added to each well, and the plate was incubated for 30 minutes.  Immediately following 
lysis, the plates were measured for fluorescence at 520 nm with a BioTek Synergy H1 Hybrid 
Multi-Mode Microplate Reader.  Data from the plate reader was then extracted into a Microsoft 
Excel spreadsheet and GraphPad Prism for analysis.  
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CHAPTER THREE: RESULTS 
Selectivity Determination of Various Nature-inspired Synthetic Compounds 
 One of the most challenging obstacles presented to drug discovery researchers is the 
discovery of a drug that not only displays potent activity against the organism of interest but one 
that also displays a high selectivity for that organism.  In light of this fact, the primary objective 
of this project was to assay the selectivity indices of the compounds obtained from the ASINEX 
chemical libraries. 
 Validation of these assays was performed in numerous manners.  The first of which was an 
overall accuracy validation via standard score (also commonly referred to as Z-factor) 
determination.  The Z-factor is obtained via the following equation: Z = 1 – 3((σc+ + σc-) / |ηc+ - 
ηc-|) where σc+ is standard deviation of the positive controls, σc- is standard deviation of negative 
controls, ηc+ is the average value of the positive controls and ηc- is the average value of the 
negative controls (Zhang, Chung et al. 1999).  This value is universally used in most research 
involving high throughput screening assays, and it ultimately determines the validity and 
accuracy of the particular assay.  The Z-factor was determined to be an average of 0.9465 for all 
MTS assays performed. According to current standards in high throughput screenings, a Z-factor 
equal to or greater than 0.5 represents an assay that is accurate enough for use in screening hits 
(Zhang, Chung et al. 1999).  The second confirmation of assay validity was provided via the 
modified Kinase-Glo assay described in Chapter Two.  Upon n=3 determination, the average Z-
factors proved to be slightly less than with the MTS assay and equal to 0.8544.  However, this 
value was still over the recommended 0.5 thus validating it’s use.  The results of the modified 
Kinase-Glo assay on the ASINEX parent compounds corresponded with the results given by the 
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MTS assays for the same compounds.  Correspondence of the two results ultimately confirms the 
validity of the MTS assay as the primary cytotoxicity assay. 
 The parent compounds were selected based upon their demonstration of >70% parasite 
inhibition at 10 μM.  From this initial parameter, nine of the most potent chemical scaffolds were 
discovered.  Following their discovery, their chemical structures were analyzed in comparison to 
the other 583 compounds within the obtained libraries, leading to the subsequent discovery of 
104 total analogs.  The exact number of analogs per parent compound is represented in Table 1 
below.  Additionally, the chemical structures along with their IUPAC nomenclature for each 
parent compound are shown in Figure 1. 
Parent Compound 
(UCF I.D. / ASINEX I.D.) 
Number of 
Analogs 
UCF 201 / LEG17217214 24 
UCF 301 / AEM12673344 3 
UCF 401 / AEM18334709 7 
UCF 501 / BAS00327426 1 
UCF 601 / BDC24040139 8 
UCF 701 / SYN23011295 4 
UCF 801 / BDD24084121 35 
UCF 901 / BAS01260479 3 
UCF 1001 / SYN15412666 19 
Total Number of Analogs 104 
 
Table 1. Each parent compound along with their respective number of structural analogs. 
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Figure 1. Chemical structures and IUPAC nomenclature of each parent compound. 
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 The first compounds to be screened for cytotoxicity against 3T3 cells were the parent 
compounds.  Each compound was assayed in triplicate concentrations on three separate 
occasions (n=3) with the average Z-factor being equal to 0.9465.  The average parasite (Dd2) 
half maximal inhibitory concentration (IC50) and mammalian (NIH 3T3) half maximal effective 
concentrations (EC50) are shown in Table 2 along with their respective selectivity indices (SI).  
However, the selectivity indices were not able to be accurately determined for UCF401, UCF701 
and UCF801 because the mammalian cell EC50s for these compounds were never reached.  
Additionally, the parent compounds which exhibited a mammalian cell EC50 of <100 μM have 
their responses plotted in Figure 2. 
ASINEX I.D. UCF I.D. 
Dd2 EC50 
(μM) 
NIH 3T3 
EC50 (μM) 
SELECTIVITY 
INDEX 
*VIABLE CELLS 
AT 100 μM (%) 
LEG 17217214 UCF 201 0.39 47 121 N/A 
AEM 12673344 UCF 301 0.39 63 161 N/A 
AEM 18334709 UCF 401 0.45 >100 >222* 73 
BAS 00327426 UCF 501 0.48 22 46 N/A 
BDC 24040139 UCF 601 0.61 38 62 N/A 
SYN 23011295 UCF 701 0.72 >100 >138* 85 
BDD 24084121 UCF 801 0.40 >100 >250* 90 
BAS 01260479 UCF 901 0.44 68 154 N/A 
SYN 15412666 UCF 1001 0.66 76 115 N/A 
 
Table 2. Parasite (Dd2) IC50s and mammalian cell (NIH 3T3) EC50s along with their corresponding selectivity 
indices.  Parasite IC50s were determined via the SYBR Green-I assay with a 10 μM CQ control.  Mammalian cell 
EC50s were determined via the MTS assay with a 60 ng/μL digitonin control.  Selectivity indices are the ratio of NIH 
3T3 EC50 to DD2 IC50.  * indicates that the selectivity index for the given compound could not be accurately 
determined due to the fact that the mammalian cell EC50 was never achieved.  However, the percentage of viable 
cells that were present at 100 μM is displayed in the last column of the table. 
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Figure 2. NIH 3T3 fibroblast toxicity in the presence of UCF201, UCF301, UCF501, UCF601, UCF901 and 
UCF1001.  Cytotoxicity was determined using the following concentrations: 10 μM, 25 μM, 50 μM, 75 μM and 100 
μM.  100 μM was the maximum concentration utilized due to toxic DMSO concentrations above this point. 
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 Subsequent screening involved the analogs of each respective parent compound. The 
average parasite IC50 and mammalian EC50 results along with the corresponding selectivity 
indices of each analog in each series are represented in Table 3.  The average Z-factor for all of 
the assays performed was 0.9465, an excellent score for high throughput screening experiments. 
ASINEX I.D. UCF I.D. 
Dd2 EC50 
(μM) 
NIH 3T3 EC50 
(μM) 
SELECTIVITY 
INDEX 
*VIABLE CELLS 
AT 100 μM (%) 
LEG 17216981 UCF 202 0.47 51 109 N/A 
LEG 17216993 UCF 203 0.99 50 51 N/A 
LEG 17217077 UCF 204 1.3 54 42 N/A 
LEG 17217088 UCF 205 0.53 53 100 N/A 
LEG 17217110 UCF 206 0.59 64 110 N/A 
LEG 17217203 UCF 207 0.75 53 71 N/A 
LEG 17217272 UCF 208 0.68 50 74 N/A 
LEG 17217283 UCF 209 0.48 51 106 N/A 
LEG 17217352 UCF 210 0.47 52 111 N/A 
LEG 17217066 UCF 211 0.93 53 57 N/A 
LEG 17217140 UCF 212 0.78 53 68 N/A 
LEG 17217152 UCF 213 0.59 53 90 N/A 
LEG 17217173 UCF 214 0.90 52 58 N/A 
LEG 17217174 UCF 215 1.1 52 46 N/A 
LEG 17217175 UCF 216 1.0 51 50 N/A 
LEG 17217176 UCF 217 0.66 52 80 N/A 
LEG 17217177 UCF 218 1.3 54 42 N/A 
LEG 17217178 UCF 219 0.82 50 61 N/A 
LEG 17217179 UCF 220 0.83 51 61 N/A 
LEG 17217180 UCF 221 1.2 53 45 N/A 
LEG 17217230 UCF 222 0.94 54 58 N/A 
LEG 17217309 UCF 223 0.64 52 81 N/A 
LEG 17217321 UCF 224 0.79 51 65 N/A 
LEG 17217341 UCF 225 0.72 51 71 N/A 
AEM 12673344 UCF 302 0.62 63 100 N/A 
AEM 12674533 UCF 303 0.57 63 111 N/A 
BAS 04246204 UCF 304 0.51 >100 >196* 90 
BDC 29760189 UCF 402 0.88 >100 >114* 85 
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LMK 17223586 UCF 403 0.94 >100 >106* 86 
LMK 17223587 UCF 404 1.1 >100 >91* 78 
LMK 17223596 UCF 405 1.1 >100 >91* 80 
LMK 17223597 UCF 406 0.73 >100 >137* 85 
LMK 17224176 UCF 407 0.85 >100 >118* 84 
LMK 17224177 UCF 408 0.71 >100 >141* 91 
BAS 00897438 UCF 502 1.1 >100 >91* 86 
BDC 24040096 UCF 602 0.69 66 96 N/A 
BDC 24040199 UCF 603 1.0 >100 >96* 83 
LMK 17223586 UCF 604 0.73 >100 >137* 91 
LMK 17223587 UCF 605 1.2 >100 >86* 87 
LMK 17223596 UCF 606 1.3 >100 >80* 72 
LMK 17223597 UCF 607 0.63 >100 >158* 92 
LMK 17224176 UCF 608 0.90 >100 >111* 95 
LMK 17224177 UCF 609 0.69 >100 >146* 89 
SYN 22931911 UCF 702 1.0 >100 >100* 80 
SYN 22981169 UCF 703 1.1 >100 >89* 85 
SYN 22981198 UCF 704 1.1 >100 >91* 77 
BAS 00371682 UCF 705 0.83 >100 >120* 81 
BDD 26909562 UCF 802 0.54 >100 >187* 93 
BDD 27574625 UCF 803 0.90 >100 >111* 96 
BDD 24084208 UCF 804 0.63 >100 >159* 79 
BDD 24084210 UCF 805 0.48 >100 >210* 68 
BDD 24084211 UCF 806 0.64 >100 >156* 72 
BDD 24084265 UCF 807 0.48 >100 >207* 96 
BDD 24084289 UCF 808 0.31 >100 >326* 92 
BDD 24084590 UCF 809 0.88 >100 >114* 77 
BDD 24084591 UCF 810 0.79 >100 >125* 82 
BDD 24084610 UCF 811 0.94 >100 >107* 79 
BDD 24084927 UCF 812 0.74 >100 >135* 76 
BDD 24084928 UCF 813 0.43 >100 >233* 98 
BDD 24085323 UCF 814 0.34 >100 >294* 76 
BDD 24085406 UCF 815 0.46 >100 >217* 85 
BDD 24085437 UCF 816 0.44 >100 >227* 69 
BDD 24085693 UCF 817 0.54 >100 >184* 77 
BDD 24085863 UCF 818 0.64 >100 >157* 80 
BDD 24085693 UCF 819 0.98 >100 >102* 95 
BDD 24085895 UCF 820 0.68 >100 >146* 87 
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BDD 24085896 UCF 821 0.67 >100 >148* 83 
BDD 24085897 UCF 822 0.44 >100 >227* 56 
BDD 26908750 UCF 823 0.74 >100 >135* 81 
BDD 26908751 UCF 824 0.94 >100 >106* 92 
BDD 26909379 UCF 825 0.49 >100 >204* 99 
BDD 26909472 UCF 826 0.54 >100 >185* 77 
BDD 26909560 UCF 827 0.53 >100 >190* 78 
BDD 26909561 UCF 828 0.65 >100 >154* 77 
BDD 24084414 UCF 829 0.41 >100 >244* 97 
BDD 24084415 UCF 830 0.47 >100 >212* 89 
BDD 24084417 UCF 831 0.64 >100 >155* 79 
BDD 24083352 UCF 832 0.59 >100 >168* 85 
BDD 24084049 UCF 833 0.52 >100 >191* 96 
BDD 24084107 UCF 834 0.58 >100 >172* 96 
BDD 24084048 UCF 835 0.83 >100 >120* 97 
BDD 24084119 UCF 836 0.63 >100 >160* 74 
BAS 01126330 UCF 902 1.3 >100 >77* 86 
BAS 00460241 UCF 903 0.66 >100 >151* 87 
BAS 00460273 UCF 904 0.78 >100 >128* 81 
SYN 15412684 UCF 1002 0.73 >100 >137* 96 
SYN 15412656 UCF 1003 0.69 >100 >144* 99 
SYN 15412520 UCF 1004 0.99 >100 >101* 95 
SYN 15412490 UCF 1005 0.82 >100 >121* 90 
SYN 15412489 UCF 1006 0.84 >100 >119* 91 
SYN 15412386 UCF 1007 0.78 >100 >128* 84 
SYN 15412385 UCF 1008 0.71 >100 >140* 94 
LMG 09142618 UCF 1009 1.1 >100 >88* 59 
LMG 09142611 UCF 1010 1.1 >100 >93* 60 
LEG 15411875 UCF 1011 0.71 >100 >140* 93 
LEG 15411860 UCF 1012 0.85 >100 >117* 86 
BAS 12416291 UCF 1013 0.69 >100 >145* 84 
BAS 01313367 UCF 1014 1.0 >100 >100* 91 
BAS 01124611 UCF 1015 0.83 >100 >120* 99 
BAS 01124862 UCF 1016 0.91 >100 >109* 95 
BAS 01124990 UCF 1017 0.82 >100 >121* 90 
BAS 01124993 UCF 1018 0.86 >100 >115* 91 
BAS 01125425 UCF 1019 0.91 >100 >109* 92 
BAS 01125538 UCF 1020 0.99 >100 >101* 89 
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Table 3.  Parasite (Dd2) and mammalian cell (NIH 3T3) EC50s along with their corresponding selectivity indices for 
all parent compound analogs.  Parasite IC50s were determined via the SYBR Green-I assay with a 10 μM CQ 
control.  Mammalian cell EC50s were determined via the MTS assay with a 60 ng/μL digitonin control.  Selectivity 
indices are the ratio of NIH 3T3 EC50 to DD2 IC50.  * indicates that the selectivity index for the given compound 
could not be accurately determined due to the fact that the mammalian cell EC50 was never achieved.  However, the 
percentage of viable cells that were present at 100 μM is displayed in the last column of the table. 
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Potential for Novel Drug Resistant Parasite Lineage 
 The most potent compound tested in the ASINEX libraries obtained, UCF201 
(LEG17217214), was also used to assay it’s potential for drug resistance development against the 
multi-drug resistant strain of P. falciparum Dd2.  Initially, the IC50 was determined to be 391 
nM, shown in Figure 3.  For comparison, the original IC50 was also determined in a drug 
sensitive strain of P. falciparum known as 3D7.  The IC50 in 3D7 was proven to be 402 nM, a 
value that is sufficiently similar to that in Dd2 to prove no significant difference exists between 
resistant and sensitive phenotypes. 
 
Figure 3.  Initial inhibition of P. falciparum Dd2 parasite growth by UCF201 (LEG17217214) via the SYBR Green-
I assay.  The initial screening concentrations were 10 nM, 100 nM, 250 nM, 500 nM, 1000 nM, 2500 nM and 5000 
nM with a 10 μM CQ control.  The intersection between the 50% parasitemia grid line and the dose-response curve 
is UCF201’s IC50 (391 nM). 
 
 Subsequent screening of the parasite that was treated with compound via the intermittent 
approach was performed during day 38 (following three seven-day cycles of treatment).  This 
secondary screening demonstrated an IC50 equal to 4.411 μM, shown in Figure 4.  This 
corresponded to an 11.28-fold increase in the parasite’s original IC50.  The intermittent resistant 
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Dd2 was assayed instead of the step-wise resistant strain for two particular reasons.  First, during 
treatment of both cultures it became obvious that the intermittent approach was seeing much 
more success than the step-wise approach.  This conclusion was reached based upon the 5X IC90 
results being displayed.  Upon treatment of both cultures with the same concentration of 
compound, the step-wise approach was seeing much more inhibition than the intermittent 
approach.  This was suggestive that a greater resistance has been generated in the intermittent 
approach.  Additionally, the availability of UCF201 at the time of screening limited application 
of the assay to only one resistant line approach. 
 
Figure 4.  Inhibition of resistant P. falciparum Dd2 parasite growth by UCF201 (LEG17217214) via the SYBR 
Green-I assay.  The screening concentrations used were 0.5 μM, 1 μM, 5 μM and 10 μM with a 10 μM CQ control.  
The intersection between the 50% parasitemia grid line and the dose-response curve is UCF201’s IC50 (4.411 μM).  
Only four concentrations (as opposed to seven in the initial screen) were used due to a limited quantity of the 
UCF201 compound at the time of screening. 
 
 The resistant parasite line was also screened against the known antimalarials CQ, MQ, 
ART and PYR to determine if there were any fluctuations in the compounds IC50s against Dd2.  
The results are presented in Table 4. 
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Standard Inhibitor Original Dd2 IC50 (nM) Resistant Dd2 IC50 (nM) Fold Increase 
Chloroquine (CQ) 382±44 402±67 0.05 
Mefloquine (MQ) 53±17 67±8 0.26 
Artemisinin (ART) 11±7 14±2 0.27 
Pyrimethamine (PYR) 2519±113 2718±214 0.08 
 
Table 4.  Comparison of standard inhibitor IC50s against the resistant Dd2 parasite.  The original Dd2 IC50s were 
determined in the same Dd2 strain which was used to generate the resistant Dd2 phenotype.  The resistant Dd2 IC50s 
were determined via the SYBR Green-I assay. 
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CHAPTER FOUR: DISCUSSION 
Compound Selectivity and Significance of Work 
 In all drug discovery research, selectivity index determination is key in preliminary 
hit screenings.  Fundamentally, the selectivity index of a compound is a measure of its 
ability to specifically inhibit a certain organism, P. falciparum in this study, while leaving 
the host of the organism unharmed or minimally affected.  More specifically, the 
selectivity index of a given compound is defined as the ratio between the in vitro 
mammalian cell (NIH 3T3) EC50 and the in vitro parasite (P. falciparum Dd2) IC50.  In 
accordance with the importance of selectivity determination, the relative selectivity 
indices of the most potent ASINEX compounds and their structural analogs was 
determined and reported herein. 
 According to the MMV’s criteria for hit compound progression, an acceptable hit 
compound IC50 for cellular parasite (Dd2) assays is less than 1 μM.  Additionally, the 
same guidelines indicate that an acceptable hit compound selectivity index is greater than 
ten.  By following the above parameters, it is possible to evaluate the data presented in 
Tables 2 & 3 and to determine which ASINEX compounds are most promising for use in 
future studies. 
 Despite each possessing a SI greater than ten, compounds 204, 215, 216, 218, 221, 
404, 405, 502, 603, 605, 606, 703, 704, 902, 1009, 1010, and 1014 can be eliminated 
from future studies based upon their demonstration of parasite IC50s greater than 1 μM.  
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All other compounds that were screened met the guidelines set forth by the MMV’s criteria for 
drug progression; each compound displayed a parasite IC50 less than 1 μM and a SI of greater 
than ten. 
 Analysis of the UCF201 series displayed the most overall cytotoxic compounds in the 
library.  The minimum EC50 (most cytotoxic or least selective) displayed within this series was 
by the parent compound itself (UCF201) at 47 μM, whereas the maximum EC50 (least cytotoxic 
or most selective) was 64 μM displayed by UCF206.  In an attempt to elucidate possible 
explanations for this slight difference, their chemical structures were empirically analyzed.  The 
difference could be due to the absence of the piperidine ring in UCF206 (Figure 5) as compared 
to it’s presence within each of the other compounds; however, confirmation of this theory will 
need to be made in any future studies involving these specific compounds. 
 
Figure 5.  Chemical structure and IUPAC nomenclature for UCF206. 
 
 The majority of the 301 series (3 out of 4) showed EC50s in the low 60 μM range.  
However, the last compound of the series, UCF304, displayed an EC50 of >100 μM.  
Examination of each compounds chemical structures to determine probable causes for the 
observed difference showed that UCF304 (Figure 6) has a morpholine ring and lacks a piperidine 
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ring, whereas the other compounds in the family lack a morpholine ring but possess a piperidine 
ring.  However, whether or not the presence or absence of the specified rings conveyed UCF304s 
marked difference in cytotoxicity remains to be determined. 
 
Figure 6.  Chemical structure and IUPAC nomenclature for UCF304. 
 
 
 Analysis of the UCF401 analogs showed no significant variations among parasite IC50s or 
mammalian cell EC50s.  However, there was a marked difference in the parent compound’s 
(UCF401) parasite IC50 compared to that of the analogs. Each analog has a parasite IC50 that is 
slightly greater than that of the parent.  Comparison of their chemical structures revealed that the 
parent compound is the only one in the family that lacks a morpholine ring (UCF408 shown in 
Figure 7 for comparison). However, whether the absence of this heterocyclic ring increased its 
antimalarial potency as opposed to other members of the family should be determined in future 
studies. 
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Figure 7.  Chemical structure and IUPAC nomenclature for UCF408. 
 
 
 The 501 series of compounds contained the most cytotoxic compound out of the entire set 
of compounds screened.  UCF501 displayed an average EC50 of 22 μM corresponding to a 
selectivity index of 46; however, the only other compound within the series (UCF502, Figure 8) 
showed a dramatic increase in both the parasite IC50 and the mammalian cell EC50, as shown in 
Table 3.  Upon analysis of their structures, the only large structural difference between the two 
was the presence of a piperazine ring in UCF502 while it was lacking in UCF501.  Despite this 
difference, it must still be confirmed in future studies whether the rings presence in UCF502 was 
the underlying cause of the variations seen. 
 
Figure 8.  Chemical structure and IUPAC nomenclature for UCF502. 
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 The UCF601 series proved to be an overall selective batch of compounds barring only two 
structures.  All compounds in this series except UCF601 and 602 demonstrated a consistent EC50 
of greater than 100 μM; UCF601 and 602 respectively displayed EC50s of 38 μM and 66 μM that 
corresponded to selectivity indices of 62 and 96, respectively.  Furthermore, the only chemical 
difference that could be empirically determined was the absence of the heterocyclic morpholine 
ring in compounds 601 and 602 (UCF607 displayed in Figure 9 for comparison).  However much 
like the other structural differences exhibited in the other series, the absence of the morpholine 
ring may not necessarily be responsible for the observed differences. 
 
Figure 9.  Chemical structure and IUPAC nomenclature of UCF607. 
 The UCF701 and UCF801 families displayed no significant variation among their 
respective parents and analogs, and, in accordance with this fact, structural analysis of each was 
not performed. 
 Both the 901 and 1001 series showed excellent selectivity indices in all compounds.  
UCF901 and UCF1001 displayed EC50s of 68 μM (SI of 154) and 76 μM (SI of 115), 
respectively; all others in both groups showed EC50s of greater than 100 μM.  Despite the 
differences seen between the parents and their respective analogs, no structural differences could 
be determined which suggests other non-empirical properties are most likely responsible.  
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However, validation of this theory must be performed in any future studies involving these 
specific compounds. 
 This study set the stage for the next step that must occur to validate each compound as a 
hit.  Following the conclusions that were made, the compounds that met the hit screening 
guidelines for parasite IC50 and SI should be further analyzed via the elucidation of their specific 
ADME (Absorption Distribution Metabolism and Excretion) profiles.  This pharmacokinetic 
profile is the final step in hit validation, and, upon adequate ADME demonstration, the most 
promising hits can be upgraded in status to an early lead compound.  As a part of a separate 
study in our drug discovery lab, ADME profiles of parent compounds UCF201, UCF301 and 
UCF401 have already been determined.  The UCF201 and UCF401 ADME profiles proved to be 
extremely promising, a fact that will ultimately lead to further studies involving these particular 
compounds.  However, UCF301’s ADME profile demonstrated its solubility as well as 
microsomal stability are inadequate for a lead compound, and it was thus eliminated from any 
future studies. 
Probability of Drug Resistance and Possible Target Elucidation of UCF201 
 Upon comparison of UCF201’s original IC50 to its’ IC50 following three seven-day rounds 
of treatment, an 11.28 fold increase was observed that is both worrisome and potentially 
insightful. 
 In order to demonstrate the mechanism of resistance to UCF201 was not due to similar 
mechanisms for known antimalarials, the intermittent resistant Dd2 line was also assayed for 
standard inhibitor IC50s.  The standard inhibitors used included CQ, MQ, ART and PYR. The 
standard inhibitor data demonstrated that there was no significant increase in the parasite IC50 for 
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the known antimalarials used, thus indicating that the specific mechanism of resistance to 
UCF201 is dissimilar to the mechanisms reported for CQ, MQ, ART and PYR. 
 The downside to this dramatic increase in parasite IC50 is the indication of an extremely 
high potential for resistance development to this specific compound.  However, studies have 
shown that certain multi-drug resistant strains, such as the Dd2 that was employed for this study, 
have a higher propensity to develop drug resistance than other strains with no prior drug 
insensitivities (Rathod, McErlean et al. 1997).  In fact, parasite phenotypes that have consistently 
developed resistance to multiple drugs are commonly referred to as ARMD (accelerated 
resistance to multiple drugs) phenotypes (Rathod, McErlean et al. 1997).  Moreover, relative 
propensities for drug resistance development to known antimalarials has been shown to be 
increased by an increase in selective pressure of a given antimalarial compound (Nzila, Nduati et 
al. 2000).  In light of this fact, the high selective pressure of 5X IC90 that was employed for the 
intermittent strain could also be a contributing factor to the extremely rapid resistance 
development that was observed.  In future studies regarding resistance emergence to UCF201, it 
will be beneficial to use a parasite phenotype that is sensitive to current antimalarials (such as 
P.falciparum 3D7).  If a sensitive parasite strain is used, it is probable that rapid resistance 
emergence will not occur, and the results obtained will be more applicable to the most prevalent 
malarial infections. 
 However, the resistance seen could also lead to the elucidation of UCF201’s specific 
target.  This could be accomplished by comparing the previously sequenced Dd2 genome to that 
of the generated resistant Dd2 parasite.  If there are any substantial genomic differences, the 
afflicted genes and proteins they encode can be determined via the Plasmodium genomic 
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database known as PlasmoDB.  Identification of the gene could potentially lead to identification 
of the drug’s target.  Some may question the practicality of sequencing an entire genome for 
these purposes.  However, our lab has recently consulted with the Genomics Division Director at 
the University of Florida, Dr. D. M. Amador, and he has deemed the task practical via the 
following assumptions: ten parasite isolates/stages are provided and two different post-Sanger 
sequencing platforms are used (he suggests Roche 454 Titanium XL and Illumina GAIIx 
platforms).  The only factor that could be an issue is the cost of such sequencing, but, even so, 
the data that can be obtained from such projects is well worth the capital. 
 However, other methods can be used to identify the drug’s specific target if genomic 
sequencing is not performed or if the results are inconclusive.  These secondary approaches 
utilize the same concepts that govern immunoprecipitation (IP) techniques.  Essentially, the 
compound of interest can be tagged with a compatible tag in such a way that the activity of the 
compound is not disrupted.  This can be confirmed by comparing the tagged drugs parasite IC50 
to that of the untagged drug.  Upon validation of similar IC50s, the tagged compound can then be 
administered to the various stages of the parasites erythrocytic life cycle.  These cells can then be 
lysed in order to obtain a crude lysate that contains all parasite proteins of the various stages 
along with the specific protein-drug (tagged) complex.  This crude lysate can then be run over an 
affinity matrix that is specific for the given compounds tag.  The affinity matrix will specifically 
interact with the drug-protein complex and effectively pull-down the drug’s target protein.  An 
alternative approach is the immobilization of the drug onto an affinity matrix such as dextran or 
agarose beads.  Following the drugs immobilization, the crude parasite lysate (with all parasitic 
proteins and protein complexes) can then be administered to this compound affinity matrix to 
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allow the protein(s) within the lysate to specifically interact with drug on the affinity column.   
Following this, the non-interacting proteins can be washed away, and the specific protein that 
interacts with the compound of interest can be eluted by applying a gradient of the target 
compound.  The eluted protein(s) can then be analyzed to identify the drug’s specific molecular 
target(s). 
 It should also be noted that this resistance development data could also be inaccurate.  
Although the assays (n=3) which were performed prior to the drug treatment are completely 
reliable, the subsequent screening was limited to n=2 after only the third round of treatment.  
These limitations were a reality because of the underlying limitations in compound availability.  
However, once more compound is synthesized and obtained it will be possible to validate these 
conclusions as well as potentially discover further resistance development that occurred after this 
experiment was performed. 
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